Navamedic ASA · OSL:NAVA

Navamedic ASA — Q4 2020 Earnings Presentation

23 slides from Navamedic ASA's earnings presentation, February 2021

  1. Slide 1: Fourth quarter results 2020

    Q4 2020 Fourth quarter results 2020 Navamedic ASA Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO 1

  2. Slide 2: Navamedic – Q4 2020 highlights

    Navamedic – Q4 2020 highlights Strong growth driven by both new products and overall • In Q4 2020, revenues grew by 17% compared to the positive performance in underlying portfolio same period last year • Strong growth for Mysimba®, Alflorex® and ThermaCare® REVENUE GROSS MARGIN EBITDA • Positive de

  3. Slide 3: Navamedic at a glance

    Navamedic at a glance Nordic pharma company targeting growth in Northern Europe Navamedic - a reliable supplier of high-quality consumer health, medical nutrition, specialty pharma and branded generics products, delivered to hospitals and through pharmacies, meeting the specific medical needs for pa

  4. Slide 4: Our growth strategy

    Our growth strategy Ambition of building a leading Nordic pharma company targeting growth in Northern Europe • Launched the new and unique women’s health product Cysticina® in Q1 2021 1 2 3 • Will launch products in at least one country in each launch window going forward STRENGTHEN THE CORE SECURE

  5. Slide 5: Continued growth for key products

    Q4 2020 Continued growth for key products Medical nutrition Consumer health Specialty pharma Branded generics Medical nutrition Gastro, pain, urology Obesity, urology Cardiology, generics product portfolio Q4 2020 YoY revenue growth: 6% Q4 2020 YoY revenue growth: 100% Q4 2020 YoY revenue growth: 27

  6. Slide 6: Medical nutrition – Positive development in most markets

    Medical nutrition – Positive development in most markets GROWTH DRIVERS Q4 2020 REVENUE • Continued growth for PKU 13.1 MNOK Sphere, without cannibalization of other PKU (Q4 2019: 12.4 MNOK) products. • Launch of PKU products in Finland. IEM Products for treatment of Inborn Errors of Metabolism (IEM

  7. Slide 7: Consumer Health - Launch of new and unique products

    Consumer Health - Launch of new and unique products GROWTH DRIVERS • Launched the new and unique UTI product Cysticina® in Q4 2020 REVENUE Norway, with an estimated addressable market of approx. 11.7 MNOK NOK 100 million* (Q4 2019: 5.8 MNOK) • ThermaCare® developing as planned • Strong performance o

  8. Slide 8: Specialty pharma – Building awareness and loyalty

    Specialty pharma – Building awareness and loyalty GROWTH DRIVERS • Strong performance of Mysimba® and Elmiron® Q4 2020 REVENUE • New extended indication 17.2 MNOK criteria for individual reimbursement in (Q4 2019: 13.6 MNOK) Norway • Information platform for health care professionals launched in Nor

  9. Slide 9: Branded Generics – Stable development and new products introduced

    Branded Generics – Stable development and new products introduced GROWTH DRIVERS Q4 2020 REVENUE • Volatility for Imdur® due 13.2 MNOK to out-of-stock situation in Q4 (Q4 2019: 14.8 MNOK) • Antibiotics portfolio introduced 9

  10. Slide 10: Financials @ Navamedic

    Financials 10 @ Navamedic

  11. Slide 11: Key consolidated profit and loss figures

    Financials • In Q4 2020, revenues increased by Key consolidated profit and loss figures 17% compared to the same quarter last year and 11% for the full year (in NOK '1000) Q4 2020 Q4 2019 YTD 2020 YTD 2019 • Gross Profit % came in above last Operating revenues 55 302 47 261 209 877 188 755 year both

  12. Slide 12: Assets

    Financials • Goodwill increase is due to currency effect, little change from Q1 onwards Assets • Shares in Associated companies has increased as a result of Navamedic’s (in NOK '1000) 31.12.2020 31.12.2019 participation in Observe Medical’s Goodwill 64 472 59 520 private placement Deferred tax asset

  13. Slide 13: Equity and liabilities

    Financials Equity and liabilities • Equity ratio of 49.8% (in NOK '1000) 31.12.2020 31.12.2019 Total equity 129 486 79 231 • Increase in Equity is mainly Non-current license liabilities 3 343 9 568 due to cash increase from the Loans and borrowings 20 870 16 092 private placement Non-current right o

  14. Slide 14: Cash flow Group – total operations

    Financials Cash flow Group – total operations • The cash flow from Operating Activities is mostly Profit before taxes coupled with the (in NOK '1000) Q4 2020 Q4 2019 Year 2020 Year 2019 changes in Net Working Capital items Net cash flow from operating activities 14 884 1 545 -3 132 12 722 Net cash f

  15. Slide 15: Summary and outlook

    Summary and outlook

  16. Slide 16: Summary and outlook

    Navamedic ASA Summary and outlook Building a leading Nordic pharma company targeting growth in Northern Europe In Q4 2020, we have • Strengthened the core by driving underlying growth in the existing portfolio • Launched new consumer health product Cysticina® in Norway • Secured uptake of newly laun

  17. Slide 17: Q&A @ Navamedic

    Q&A 17 @ Navamedic

  18. Slide 18: Thank you for your attention!

    Thank you for your attention! Navamedic’s Q1 2021 presentation will be on 11 May, 2021 18

  19. Slide 19: Appendix

    Appendix

  20. Slide 20: Condensed consolidated statement of comprehensive income

    Navamedic ASA Condensed consolidated statement of comprehensive income (in NOK '1000) Q4 2020 Q4 2019 YTD 2020 YTD 2019 Operating revenues 55 302 47 261 209 877 188 755 Total revenue 55 302 47 261 209 877 188 755 Cost of materials -32 978 -33 247 -139 538 -131 152 Gross profit 22 324 14 014 70 339 5

  21. Slide 21: Condensed consolidated statement of cash flows

    Navamedic ASA Condensed consolidated statement of cash flows (in NOK '1000) Q4 2020 Q4 2019 Year 2020 Year 2019 Cash flow from operating activities Profit before tax continuing operations -4 561 -1 773 -16 596 -15 477 Taxes paid 1 643 2 080 -239 329 Depreciation, amortization and impairment 919 -1 0

  22. Slide 22: Basis for preparation and Alternative Performance Measures

    Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres

  23. Slide 23: Copyright and disclaimer

    Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any

Navamedic — Q4 2020 Earnings Presentation on 6ix